S&P 500

5.318,99

0,23%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Bolt Biotherapeutics Inc (BOLT)
Bolt Biotherapeutics Inc (BOLT) Notícias

BOLT

Bolt Biotherapeutics (BOLT)

Bolt Biotherapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:BOLT

1 2 3 4 5 6 7 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
20/05/2024	14:22	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:BOLT	Bolt Biotherapeutics Inc
15/05/2024	18:43	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:BOLT	Bolt Biotherapeutics Inc
14/05/2024	17:14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BOLT	Bolt Biotherapeutics Inc
14/05/2024	17:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BOLT	Bolt Biotherapeutics Inc
14/05/2024	17:05	GlobeNewswire Inc.	Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team	NASDAQ:BOLT	Bolt Biotherapeutics Inc
21/03/2024	17:05	GlobeNewswire Inc.	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	NASDAQ:BOLT	Bolt Biotherapeutics Inc
06/03/2024	15:29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BOLT	Bolt Biotherapeutics Inc
27/02/2024	09:00	GlobeNewswire Inc.	Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference	NASDAQ:BOLT	Bolt Biotherapeutics Inc
12/02/2024	23:41	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:BOLT	Bolt Biotherapeutics Inc
06/02/2024	15:09	Edgar (US Regulatory)	Form 5 - Annual statement of changes in beneficial ownership of securities	NASDAQ:BOLT	Bolt Biotherapeutics Inc
21/12/2023	09:30	GlobeNewswire Inc.	Pacira Appoints Frank D. Lee as Chief Executive Officer	NASDAQ:BOLT	Bolt Biotherapeutics Inc
05/12/2023	09:00	GlobeNewswire Inc.	Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®	NASDAQ:BOLT	Bolt Biotherapeutics Inc
09/11/2023	18:05	GlobeNewswire Inc.	Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:BOLT	Bolt Biotherapeutics Inc
07/11/2023	09:00	GlobeNewswire Inc.	Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference	NASDAQ:BOLT	Bolt Biotherapeutics Inc
23/10/2023	11:30	GlobeNewswire Inc.	Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	NASDAQ:BOLT	Bolt Biotherapeutics Inc
18/10/2023	08:00	GlobeNewswire Inc.	Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting	NASDAQ:BOLT	Bolt Biotherapeutics Inc
17/10/2023	08:00	GlobeNewswire Inc.	Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers	NASDAQ:BOLT	Bolt Biotherapeutics Inc
16/10/2023	08:00	GlobeNewswire Inc.	Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023	NASDAQ:BOLT	Bolt Biotherapeutics Inc
28/09/2023	08:00	GlobeNewswire Inc.	Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers	NASDAQ:BOLT	Bolt Biotherapeutics Inc
12/09/2023	09:05	GlobeNewswire Inc.	Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042	NASDAQ:BOLT	Bolt Biotherapeutics Inc
05/09/2023	17:15	GlobeNewswire Inc.	Bolt Biotherapeutics to Participate in September Investor Conferences	NASDAQ:BOLT	Bolt Biotherapeutics Inc
07/08/2023	17:10	GlobeNewswire Inc.	Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	NASDAQ:BOLT	Bolt Biotherapeutics Inc
03/08/2023	08:30	GlobeNewswire Inc.	Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer	NASDAQ:BOLT	Bolt Biotherapeutics Inc
31/07/2023	18:27	GlobeNewswire Inc.	Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023	NASDAQ:BOLT	Bolt Biotherapeutics Inc
14/06/2023	18:22	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BOLT	Bolt Biotherapeutics Inc
13/06/2023	17:56	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BOLT	Bolt Biotherapeutics Inc
30/05/2023	09:00	PR Newswire (US)	BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases	NASDAQ:BOLT	Bolt Biotherapeutics Inc
25/05/2023	18:05	GlobeNewswire Inc.	Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting	NASDAQ:BOLT	Bolt Biotherapeutics Inc
11/05/2023	17:05	GlobeNewswire Inc.	Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update	NASDAQ:BOLT	Bolt Biotherapeutics Inc
28/04/2023	17:18	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:BOLT	Bolt Biotherapeutics Inc